Indaptus Therapeutics, Inc. (INDP)
NASDAQ: INDP · IEX Real-Time Price · USD
2.440
-0.270 (-9.96%)
Apr 5, 2024, 3:59 PM EDT - Market closed

Company Description

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products.

Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial.

The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021.

Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Indaptus Therapeutics, Inc.
Indaptus Therapeutics logo
Country United States
Founded 2000
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Jeffrey A. Meckler

Contact Details

Address:
3 Columbus Circle, 15th Floor
New York, New York 10019
United States
Phone (646) 427-2727
Website indaptusrx.com

Stock Details

Ticker Symbol INDP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001857044
CUSIP Number 45339J105
ISIN Number US45339J1051
Employer ID 86-3158720
SIC Code 2834

Key Executives

Name Position
Jeffrey A. Meckler Chief Executive Officer and Director
Walt Addison Linscott Esq. Chief Operating Officer
Dr. Michael J. Newman Ph.D. Founder, Chief Scientific Officer and Director
Nir Sassi Chief Financial Officer, Secretary and Treasurer
Dr. Roger J. Waltzman M.B.A., M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 25, 2024 8-K Current Report
Mar 13, 2024 424B5 Filing
Mar 13, 2024 10-K Annual Report
Mar 13, 2024 8-K Current Report
Mar 4, 2024 8-K Current Report
Jan 23, 2024 8-K Current Report
Nov 6, 2023 10-Q Quarterly Report
Nov 6, 2023 8-K Current Report
Nov 6, 2023 8-K Current Report
Oct 31, 2023 8-K Current Report